Prices are updated after-hours

Health Technology 2014

Bellicum Pharmaceuticals, Inc.

BLCM | $0.0748 381.28% 6.1K

(0.0% 1d) (0.0% 1m) (-77.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (3229.12% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 726,826
http://www.bellicum.com
Sec Filling | Patents | 107 employees

(US) Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.

cancer immunotherapy

add to watch list Paper trade email alert is off

Applied Genetic Technologies Corporation

AGTC | News | $0.3936 1.23% 0.0%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-80.43% volume)
Earnings Calendar: 2022-11-08
Market Cap:
http://www.agtc.com
Sec Filling | Patents | 83 employees

(US) Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the development of gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. It has clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL.

gene therapies genetic clinical trials

add to watch list Paper trade email alert is off

Aravive, Inc.

ARAV | $0.0401 4.74% 4M

Health Technology

(0.0% 1d) (0.0% 1m) (-97.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-85.6% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 2,949,862
http://www.aravive.com
Sec Filling | Patents | 17 employees

(US) Aravive, Inc. is a clinical-stage biotechnology company, which engages in developing new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments, and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.

cancer t-cell ovarian cancer treatment ceiling

add to watch list Paper trade email alert is off

Concert Pharmaceuticals, Inc.

CNCE | $8.37 0.36% 0

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (16.76% volume)
Earnings Calendar: 2023-03-02
Market Cap: $ 520,711,745
http://www.concertpharma.com
Sec Filling | Patents | 70 employees

(US) Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

autoimmunity nervous system molecule drugs

add to watch list Paper trade email alert is off

ContraFect Corporation

CFRX | $0.05 0.0% 910K

Health Technology

(0.0% 1d) (0.0% 1m) (-96.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (2396.14% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 535,240
http://www.contrafect.com
Sec Filling | Patents | 24 employees

(US) ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.

antibody monoclonal antibodies infectious disease influenza treatment bloodstream injection

add to watch list Paper trade email alert is off

Forward Pharma A/S

FWP | $1.95 7.74% 7.18%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-64.55% volume)
Earnings Calendar:
Market Cap: $ 13,827,811
http://www.forward-pharma.com
Sec Filling | Patents | 5 employees

(DK) Forward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. It focuses on the immunomodulatory compound dimethyl fumarate and its derivatives. The company was founded by Florian Schönharting on July 1, 2005 and is headquartered in Copenhagen, Denmark.

neurological treatment

add to watch list Paper trade email alert is off

Genocea Biosciences, Inc.

GNCA | $0.051

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-15.0% 3d) (0.0% 7d) (-35.74% volume)
Earnings Calendar: 2022-08-04
Market Cap:
http://www.genocea.com
Sec Filling | Patents | 59 employees

(US) Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.

vaccine cancer immunotherapy t-cell genetic treatment ceiling

add to watch list Paper trade email alert is off

Otonomy, Inc.

OTIC | $0.077

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-11.6% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar: 2023-02-28
Market Cap: $ 4,400,819
http://www.otonomy.com
Sec Filling | Patents | 49 employees

Otonomy, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Ménière's disease; OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT); OTO-313 (gacyclidine) tinnitus; OTO-413 (BDNF) hidden hearing Loss; OTO-510 (otoprotectant) prevent CIHL; OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan in April 2008 and is headquartered in San Diego, CA.

t-cell brands hearing loss ceiling

Drugs

Otiprio (ciprofloxacin)

add to watch list Paper trade email alert is off

PLx Pharma Inc.

PLXP | $0.087 -4.6% 50M

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (Infinity% volume)
Earnings Calendar: 2023-04-17
Market Cap: $ 2,534,979
http://www.plxpharma.com
Sec Filling | Patents | 12 employees

(US) PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.

gastrointestinal

add to watch list Paper trade email alert is off

Quotient Limited

QTNT | $0.38 2.73% -5.45%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (6319.76% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 51,604,836
http://www.quotientbd.com
Sec Filling | Patents | 418 employees

(CH) Quotient Ltd. is a commercial-stage diagnostics company. It provides immunohematology products to hospitals and blood banks. The firm develops, manufactures and sells conventional reagent products to equipment manufacturers. It engages in transfusion diagnostics, which focuses on blood grouping and serological disease screening. The company was founded on January 18, 2012 and is headquartered in Eysins, Switzerland.

diagnostics

add to watch list Paper trade email alert is off

Second Sight Medical Products, Inc.

EYES | $4.14 -0.24% 3.14%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (Infinity% volume)
Earnings Calendar:
Market Cap:
http://www.secondsight.com
Sec Filling | Patents | 112 employees

Second Sight Medical Products, Inc. engages in the development, manufacture, and marketing of implantable visual prosthetics. It operates through the following geographical segments: United States, Italy, France, and China. The firm's product include Argus II Retinal Prosthesis System that treats outer retinal degenerations, such as retinitis pigmentosa, also referred to as RP. The company was founded by Alfred E. Mann, Aaron Mendelsohn, Sam Williams, Robert J. Greenberg, and Gunnar Bjorg in 1998 and is headquartered in Sylmar, CA.

china prosthetics

add to watch list Paper trade email alert is off

Sientra, Inc.

SIEN | $0.174 0.69% 3.4M

Health Technology

(0.0% 1d) (0.0% 1m) (-84.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-96.6% volume)
Earnings Calendar: 2023-11-14
Market Cap: $ 2,080,642
http://www.sientra.com
Sec Filling | Patents | 339 employees

(United States) Sientra, Inc. operates as a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. It operates through two reportable segments: Breast Products and miraDry. The Breast Products segment focuses on sales of its breast implants, tissue expanders and scar management products under the brands Sientra, AlloX2, Dermaspan, Softspan and BIOCORNEUM. The miraDry segment focuses on sales of the miraDry System, consisting of a console and a handheld device which uses consumable single-use bioTips. The company was founded by Hani M. Zeini on August 29, 2003 and is headquartered in Santa Barbara, CA.

aesthetic brands msa

Drugs

BIOCORNEUM ADVANCED SCAR TREATMENT ANTI-ITCH (Hydrocortisone acetate 1%)
BIOCORNEUM PLUS SPF 30 ADVANCED SCAR TREATMENT (Octinoxate Octisalate Octocrylene Oxybenzone)

add to watch list Paper trade email alert is off

Affimed N.V.

AFMD | $4.91 -8.22% -8.96% 65K

Health Technology

(0.0% 1d) (-8.3% 1m) (425.9% 1y) (0.0% 2d) (-6.5% 3d) (-5.2% 7d) (Infinity% volume)
Earnings Calendar: 2024-03-21
Market Cap: $ 74,766,843
http://www.affimed.com
Sec Filling | Patents | 128 employees

(DE) Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

cancer immunotherapy t-cell ceiling

add to watch list Paper trade email alert is off

Agile Therapeutics, Inc.

AGRX | $0.37 0.0% 95K

Health Technology

(0.0% 1d) (19.8% 1m) (-93.9% 1y) (0.0% 2d) (8.1% 3d) (5.3% 7d) (-22.23% volume)
Earnings Calendar: 2024-03-21
Market Cap: $ 2,536,805
http://www.agiletherapeutics.com
Sec Filling | Patents | 15 employees

(US) Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.

contraception

Drugs

Twirla (levonorgestrel/ethinyl estradiol)

add to watch list Paper trade email alert is off

Akebia Therapeutics, Inc.

AKBA | $1.36 -0.73% -0.74% 1.5M

Health Technology

(0.0% 1d) (-31.5% 1m) (72.8% 1y) (0.0% 2d) (0.0% 3d) (0.7% 7d) (Infinity% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 284,746,294
http://www.akebia.com
Sec Filling | Patents | 360 employees

(US) Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

kidney diseases renal metabolic treatment rice kidney

add to watch list Paper trade email alert is off

Aldeyra Therapeutics, Inc.

ALDX | $3.93 0.51% 0.51% 570K

Health Technology

(0.0% 1d) (34.9% 1m) (-56.6% 1y) (0.0% 2d) (0.8% 3d) (2.1% 7d) (26.15% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 233,498,942
http://www.aldeyra.com
Sec Filling | Patents | 20 employees

Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

msa

add to watch list Paper trade email alert is off

Amphastar Pharmaceuticals, Inc.

AMPH | $40.98 0.17% 0.17% 220K

Health Technology

(0.0% 1d) (-5.1% 1m) (7.4% 1y) (0.0% 2d) (0.2% 3d) (2.5% 7d) (3.86% volume)
Earnings Calendar: 2024-02-28
Market Cap: $ 2,002,526,139
http://www.amphastar.com
Sec Filling | Patents | 2027 employees

(US) Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets and distributes enoxaparin, cortrosyn, amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment manufactures and distributes recombinant human insulin and porcine insulin. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

hypoglycemia insulin profitable injection

Drugs

AMPHADASE (hyaluronidase)
Cortrosyn (Cosyntropin)
Enoxaparin Sodium (enoxaparin sodium)
Enoxaparin Sodium (Enoxaparin sodium)
Glucagon (Glucagon)
ISOPROTERENOL HYDROCHLORIDE (Isoproterenol Hydrochloride)
Medroxyprogesterone Acetate (Medroxyprogesterone acetate)
NEOSTIGMINE METHYLSULFATE (neostigmine methylsulfate)

add to watch list Paper trade email alert is off

Ardelyx, Inc.

ARDX | $6.43 0.63% 0.62% 5.4M

Health Technology

(0.0% 1d) (-13.3% 1m) (38.0% 1y) (0.0% 2d) (0.6% 3d) (-0.8% 7d) (42.35% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 1,496,171,031
http://www.ardelyx.com
Sec Filling | Patents | 88 employees

(US) Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.

treatment

Drugs

IBSRELA (tenapanor hydrochloride)

add to watch list Paper trade email alert is off

Atara Biotherapeutics, Inc.

ATRA | $0.7101 -1.18% -1.2% 700K

Health Technology

(0.0% 1d) (7.4% 1m) (-74.0% 1y) (0.0% 2d) (-1.4% 3d) (7.6% 7d) (-16.3% volume)
Earnings Calendar: 2024-02-08
Market Cap: $ 84,756,989
http://www.atarabio.com
Sec Filling | Patents | 393 employees

(US) Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.

cancer autoimmunity msa

add to watch list Paper trade email alert is off

Avanos Medical, Inc.

AVNS | $18.71 -0.27% 0.0% 170K

Health Technology

(0.0% 1d) (-4.5% 1m) (-36.1% 1y) (0.0% 2d) (-0.3% 3d) (0.0% 7d) (35.16% volume)
Earnings Calendar:
Market Cap: $ 864,457,980
http://www.avanos.com
Sec Filling | Patents | 4700 employees

(US) Avanos Medical, Inc. is a medical technology company, which focuses on delivering clinically medical device solutions to improve patients' quality of life. Its portfolio of innovative product offerings focused on respiratory and digestive health, along with surgical and interventional pain management to improve patient outcomes and reduce the cost of care. Its brands include ON-Q, Coolife, Microcuff, MIC-Key, Quilbloc and Home pump. The company was founded on February 25, 2014 and is headquartered in Alpharetta, GA.

education respiratory brands

add to watch list Paper trade email alert is off